Changes

no edit summary
Line 1,550: Line 1,550:  
|[[HAEM5:In situ follicular B-cell neoplasm|In situ follicular B-cell neoplasm]]
 
|[[HAEM5:In situ follicular B-cell neoplasm|In situ follicular B-cell neoplasm]]
 
|Disease
 
|Disease
 +
|Rachel D. Burnside, PhD, MBA, FACMGG
 +
|7/28/2023
 
|
 
|
|
+
|Pending
|
  −
|
   
|
 
|
 
|SG
 
|SG
 
|
 
|
 
|
 
|
|In situ follicular B-cell neoplasm
+
|In Situ Follicular Neoplasia
 
|Rachel D. Burnside, PhD, MBA, FACMGG
 
|Rachel D. Burnside, PhD, MBA, FACMGG
 
|Pending
 
|Pending
 
|
 
|
|Author assigned on 7/28/2023
+
|
 
|-
 
|-
 
|[[HAEM5:Follicular lymphoma|Follicular lymphoma]]
 
|[[HAEM5:Follicular lymphoma|Follicular lymphoma]]
 
|Disease
 
|Disease
 +
|Rachel D. Burnside, PhD, MBA, FACMGG
 +
|7/28/2023
 
|
 
|
|
+
|Pending
|
  −
|
   
|
 
|
 
|SG
 
|SG
 
|
 
|
|
+
|Author also needs to correlate with 4th edition disease "Testicular Follicular Lymphoma", which is no longer a separate entity
|
+
|Follicular Lymphoma + Testicular Follicular Lymphoma
 
|Ruthann Pfau, PhD, FACMG, Nationwide Children's Hospital  Rachel D. Burnside, PhD, MBA, FACMG, University of Florida
 
|Ruthann Pfau, PhD, FACMG, Nationwide Children's Hospital  Rachel D. Burnside, PhD, MBA, FACMG, University of Florida
|
+
|Pending
 
|
 
|
 
|
 
|